Brincidofovir

Drug Profile

Brincidofovir

Alternative Names: BCV; Cidofovir hexadecyloxypropyl ester; Cidofovir PIM conjugate; CMX-001; HDP-CDV; HDP-cidofovir; Hexadecyl-oxypropyl cidofovir - Chimerix

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator University of California, San Diego
  • Developer Centers for Disease Control and Prevention; Chimerix; National Institutes of Health (USA); University of Oxford
  • Class Antivirals; Phosphonic acids; Pyrimidinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections; Adenovirus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Adenovirus infections; Cytomegalovirus infections; Smallpox
  • Phase II/III Viral infections
  • No development reported Human polyomavirus infections
  • Discontinued Ebola virus infections

Most Recent Events

  • 06 Jan 2017 Preliminary adverse events data from a phase I trial in Cytomegalovirus infections (In volunteers) released by Chimerix (IV)
  • 29 Nov 2016 Phase-I clinical trials in Cytomegalovirus infections (In volunteers) in New Zealand (IV) (ACTRN12616001657415)
  • 27 Oct 2016 Interim adverse events and efficacy data from the phase III AdVise trial in Adenovirus infections presented at the Infectious Disease Conference-2016 (IDW-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top